Tirzepatide is a novel long-acting peptide engineered as a dual agonist targeting both GLP?1 and GIP receptors. Unlike single-target GLP-1 analogues, this molecule activates two distinct metabolic signalling pathways simultaneously, making it a popular research compound for preclinical metabolic and energy balance investigations. The structure incorporates a fatty acid moiety for albumin binding, which extends its circulation half-life in biological fluid models, a key feature widely studied in peptide pharmacokinetics research.

Laboratory studies focus on its effects on glucose homeostasis, appetite regulation and lipid metabolism. Researchers utilize this peptide for cell-level receptor activation assays, animal model metabolic assessments, and peptide drug delivery system exploration. Its modified peptide backbone is more resistant to enzymatic degradation compared to native endogenous GLP-1.

Produced via solid-phase peptide synthesis followed by reversed-phase chromatographic purification and lyophilization. The freeze-dried form stabilizes the peptide and the lipid side chain. After reconstitution, separate the solution into single-use aliquots. Repeated freeze-thaw cycles will damage the fatty acid modification and reduce biological activity. Handle the powder under low humidity conditions to avoid premature hydrolysis.